Purpose: Chromosomal microarray (CMA) testing provides the highest diagnostic yield for clinical testing of patients with developmental delay (DD), intellectual disability (ID), multiple congenital ...

Microarray-based comparative genomic hybridization (CGH microarray) is an evolving technology for the rapid multiplex detection of genomic imbalances. 1 This diagnostic strategy has contributed to our ...

CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

As per precedence Research, the global DNA microarray market size is projected to grow approximately USD 6.13 billion by 2034 from valued at USD 2.28 billion in 2023. It is expanding at a CAGR of 9.4% ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...

Current prenatal testing involves the collection of chorionic villi, amniotic fluid or fetal blood and the culture of these cells to obtain metaphase chromosomes for analysis. Through cytogenetic ...